<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Little information is available regarding whether an unrelated cord blood (UCB) unit or a related donor with a 1-antigen mismatch at the HLA-A, HLA-B or HLA-DR locus in the graft-versus-host direction (RD/1AG-MM-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GVH</z:e>) should be selected as an alternative donor for patients without an HLA-matched related/unrelated donor </plain></SENT>
<SENT sid="1" pm="."><plain>Therefore, we conducted a retrospective study using national registry data on patients with <z:hpo ids='HP_0001909'>leukemia</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> who received transplantation using a single UCB (n=2288) unit or an RD/1AG-MM-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GVH</z:e> (n=525) </plain></SENT>
<SENT sid="2" pm="."><plain>We found that the survival rate in the UCB group was comparable to that in the RD/1AG-MM-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GVH</z:e> group, although the RD/1AG-MM-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GVH</z:e> group with an HLA-B mismatch showed significantly higher overall and non-relapse mortality </plain></SENT>
<SENT sid="3" pm="."><plain>Neutrophil and platelet engraftment were significantly faster, whereas the incidence of <z:hpo ids='HP_0011009'>acute</z:hpo> or <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) was significantly higher in the RD/1AG-MM-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GVH</z:e> group </plain></SENT>
<SENT sid="4" pm="."><plain>The incidence of <z:hpo ids='HP_0011009'>acute</z:hpo> or <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD in the RD/1AG-MM-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GVH</z:e> group with in vivo T-cell <z:mpath ids='MPATH_63'>depletion</z:mpath> was comparable to that in the UCB group, which translated into a trend toward better overall survival, regardless of the presence of an HLA-B mismatch </plain></SENT>
<SENT sid="5" pm="."><plain>In conclusion, UCB and RD/1AG-MM-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GVH</z:e> are comparable for use as an alternative donor, except for RD/1AG-MM-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GVH</z:e> involving an HLA-B mismatch </plain></SENT>
</text></document>